Clinical Trial Search

Primary: Pain Outcome: Visual Analog Scale — 3.5; 2 score on a scale

Primary: Scar Comparison Between Treatment Arms, as Measured by the Patient and Observer Scar Assessment Scale (POSAS) — 27.2; 45.0; 31.2; 44.8 score on a scale — p=0.013

Primary: Number of Participants With no Symptoms of Trigger Finger — 28; 9 Participants

Primary: Early Disease: Nodule Hardness at 12 Months — 58.1; 61.2 Durometer Arbitrary Units (AU)

Primary: Incidence of Pain — 6; 11 Participants

Primary: Disabilities of the Arm, Shoulder, and Hand (DASH) Questionnaire — 28; 29 units on a scale

Primary: The Measured Change in Volume of the Cord by MRI Before and After XIAFLEX Injection and Manual Manipulation. — 482 mm^3 — p=<0.0013

Primary: Disabilities of the Arm, Shoulder, and Hand (DASH) Questionnaire — 18; 13 units on a scale

Primary: Cortical Silent Period — 9; 1.61 milliseconds

Primary: Number Patients Obtaining Clinical Improvement (>50% Reduction in Contracture) — 5; 1 participants

Primary: Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection — 64; 6.8 Percentage of Joints — p=<0.001

Primary: Extension Deficit in the Affected Distal Interphalangeal Joint. — 12; 10 degrees extension deficit

Primary: Symptom Severity and Limitations in Hand Function as Assessed by the BCTQ 6 Weeks — 2.02; 2.29 score on a scale — p=<0.001

Primary: Factors Associated With Eaton Classification of Trapeziometacarpal Arthrosis: Age — 61; 66; 75 Years

Primary: Change in Elbow Pain Using Visual Analog Scale (VAS) — 5.1; 3.0; 1.9; 1.1 VAS Score

Primary: Comparison of Range of Motion of the Shoulder — 61; 49; 80; 64 degrees

Primary: Australian Canadian OA Hand Index (AUSCAN) — 3.3; 1.3; 2.0; 1.6 score on a scale

Primary: Hand Function — 5.54; 2.69 units on a scale

Primary: Numeric Pain Rating Scale — 1.7; 2.4; 3.2 units on a scale — p=0.6

Primary: Equivalency of 4DCT-based Treatment Plan to Arthroscopic-based Treatment Plan. — 5; 14; 11 Participants

Primary: Total Passive Extension Deficit (TPED) at Baseline for First Injection — 55.0 degrees

Primary: Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ-SSS) Change — -1.5; -1.5 units on a scale — p=0.46

Primary: Change in SSS of the BCTQ at 28 Days vs Baseline — 0.59; 0.93; .00 point decrease in SSS

Primary: Postoperative Follow-Up Retention Rate — 17; 13; 0; 2 thumbs

Primary: Action Research Arm Test (ARAT) — 3.5; 0.8 score on a scale

Primary: Percent Change From Baseline in Total Fixed Flexion — 74.41 percentage of contracture change

Primary: Reduction in Contracture to 5° or Less — 52.7 percentage of joints

Primary: Numeric Rating Scale for Pain — 3.2; 2.1 score on a scale

Primary: Boston Carpal Tunnel Questionnaire - Symptom Severity Scale (BCTQ-SSS) — -1.543 units on a scale

Primary: Motor and Strength Outcome Measure Using Box and Block Test Measured in Units of Blocks Placed — 2.3; 2.4 blocks